IsoTis
OrthoBiologics (SWX/Euronext Amsterdam: ISON; TSX: ISO) announces the
signing of a commercial alliance with Teknimed to jointly develop
synthetic-based products for use in orthopedic, spine, and trauma surgery.
Teknimed, a French company based in Toulouse (www.teknimed.com), is a
leading developer and OEM ("original equipment manufacturer") of calcium
phosphates and other biomaterial based products.

Jacques Essinger, Chief Executive Officer and President US of IsoTis
Orthobiologics, said: "The agreement with Teknimed allows us to more rapidly
expand our OsSatura product family. It will give our sales force a larger
portfolio to address a broader range of orthopaedic indications. This is in
line with our stated objective to increase the contribution of synthetic
products to our global product sales mix. The alliance is also of strategic
importance as it enables IsoTis to further explore development with one of
the leading companies in the field of innovative products complementary to
our in-house programs."